DeCure for Metaphyseal chondrodysplasia, Jansen type
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for metaphyseal chondrodysplasia, Jansen type — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMetaphyseal chondrodysplasia, Jansen type maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for metaphyseal chondrodysplasia, jansen type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
myosin light chain 3 (MYL3) — MYL3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9TPJ · 3.02 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A mother and infant girl with Jansen-type metaphyseal chondrodysplasia were described in 1984, confirming dominant inheritance. The radiographic signs were obvious at birth, but the marked metaphyseal calcifications characteristic of middle childhood were absent at both extremes of age. A 1959 case report proposed the name metaphyseal chondrodysplasia of Jansen and described biochemical changes simulating hyperparathyroidism—hypercalcaemia and hypophosphataemia—but parathyroid exploration found no hyperplasia or adenoma. The author postulated that the metabolic changes might be secondary to the underlying bone defect. A 2016 article on anaesthesia management noted that hyperkalemia and hypophosphataemia are seen in most patients and drew attention to anaesthesia-related issues in a 9-year-old with the condition.
No treatment or intervention was tested in any of these reports. The 1959 case is a single observation; the 1984 report is a two-generation family description; the 2016 article is a clinical note on anaesthesia. There are no data on survival, response rates, or sample sizes beyond these few individuals. The metabolic abnormalities are described but not explained at a molecular level, and no mechanism has been confirmed.
What is still missing is a molecular understanding of the disorder that could point to a drug target, any clinical trial of a repurposed or novel agent, and a patient registry large enough to stratify by age or severity. Without these, the condition remains a descriptive diagnosis with no evidence-based treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1984 · 48 citations
The Jansen type of metaphyseal chondrodysplasia: Confirmation of dominant inheritance and review of radiographic manifestations in the newborn and adult
AbstractWe describe a mother and infant girl with the Jansen type of metaphyseal chondrodysplasia. The transmission of the syndrome from mother to daughter in this family establishes this as a dominant condition. Characteristic radiographic manifestations of the disorder were obvious at birth. The mother and infant illustrate the two extremes of age where the radiographic manifestations are less characteristic than in middle childhood, since the marked metaphyseal calcifications are absent.
Journal of Bone and Joint Surgery · 1959 · 46 citations
Metaphyseal Chondrodysplasia of Jansen
Abstract1. A case is described for which the name metaphyscal chondrodysplasia of Jansen is suggested. 2. Biochemical changes were found simulating those caused by hyperparathyroidism, but different and distinctive roentgenographic findings were also evident. Parathyroid exploration was negative for hyperplasia or adenoma. 3. It is postulated that the metabolic changes—hypercalcaemia and hypophosphataemia—may have been secondary to the unverlying bone defect.
Eastern Journal Of Medicine · 2016 · 1 citations · open access
Anesthesia management of Jansen’s metaphyseal dysplasia
AbstractMetaphyseal chondrodysplasia is a rare autosomal dominant disorder characterized by accumulation of cartilage in specifically metaphysis of tubular bones. Hyperkalemia and hypophosphatemia were seen most of these patients. In this article we intended to draw attention to some issues releated with anesthesia hereby that a 9 year-old patient with Jansen's metaphyseal dysplasia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
